Abstracts tagged "polymyalgia rheumatica and tocilizumab"

Abstract Number: 804 • 2017 ACR/ARHP Annual Meeting
The Efficacy and Safety of the Anti-IL-6 Receptor Antibody Tocilizumab for Polymyalgia Rheumatica Patients with Resistance or Intolerance to Glucocorticoids and Methotrexate
Manami Hirata¹, Akiko Ueno², kazuyuki fujita², Nobuyuki Shibutou² and Masahiro Yamamura³, ¹Center for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ²Centor for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ³Okayama Saiseikai General Hospital, Okayama, Japan
Background/Purpose: Some patients show inadequate responses to initial glucocorticoids (GC) doses or relapses during GC tapering and develop side effects of GCs. The 2015 EULAR/ACR…
Abstract Number: 1985 • 2015 ACR/ARHP Annual Meeting
Abnormal B-Cell Distribution Is Improved By Tocilizumab Monotherapy in Patients with Polymyalgia Rheumatica
Guillermo Carvajal Alegria¹, Valerie Devauchelle², Yves Renaudineau³, Alain Saraux⁴, Jacques-Olivier Pers⁵ and Divi Cornec⁶, ¹Immunology, CHRU MORVAN, BREST, France, ²Service de Rhumatologie, CHU Brest, Brest, France, ³Immunology, Brest University Medical School Hospital, Brest, France, ⁴Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁵EA2216/ERI29 UBO, Brest, France, ⁶Department of rheumatology, Brest Occidentale University, Brest, France
Background/Purpose: Abnormalities in B-cell population distribution were recently reported in polymyalgia rheumatica (PMR) and giant cell arteritis, which improved with glucocorticoids. Our objective here was…
Abstract Number: 1986 • 2015 ACR/ARHP Annual Meeting
Clinical Efficacy of Tocilizumab in Polymyalgia Rheumatica: An OPEN-Label Study.
Eric Toussirot¹, Antoine Martin², Martin Soubrier³, serge redeker⁴, Alexis Régent⁵ and Le CRI⁶, ¹Service de Rhumatologie, CHU J Minjoz, Besancon, France, ²Rheumatology, Centre Hospitalier, St Brieuc, France, ³Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴43 rue de l'isle, Ch Abbeville, Abbeville, France, ⁵Paris Descartes University, UPRES-EA 4058, Paris, France, ⁶Rheumatology, CHU, Strasbourg, France
Background/Purpose: polymyalgia rheumatic (PMR) is a chronic inflammatory disorder of unknown etiology that affects elderly people. Glucocorticoids (GC) are still the mainstay of therapy for…
Abstract Number: 3144 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab for Polymyalgia Rheumatica
Lindsay Lally¹, Lindsy J. Forbess², Chris Hatzis¹ and Robert F. Spiera³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Rheumatology, HSS, New York, NY
Background/Purpose: IL-6 is a pivotal cytokine in PMR pathogenesis, yet the efficacy of IL-6 blockade with tocilizumab (TCZ) for treatment of PMR is unknown. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].